Inotrem nangibotide program gets Fast Track designation from the FDA
Category: #health  By Pankaj Singh  Date: 2019-09-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Inotrem nangibotide program gets Fast Track designation from the FDA
  • The company’s therapeutic solution is capable of being the first septic shock treatment which is mechanism-based.
     
  • Inotrem will start its planned multinational multicentric Phase IIb trial in patients of septic shock later in 2019.

Inotrem S.A., a biotech firm that specializes in immunotherapy for chronic and acute inflammatory syndromes, reportedly announced that the United States Food and Drug Administration (FDA) assigned Fast Track designation for its nangibotide development program that would work to treat septic shock.

Septic shock is the subsequent complication of sepsis. Septic shock incidence is continuously increasing, and its mortality is high (35%) in developed countries. No specific therapy is currently approved for this indication except symptomatic and antibiotics treatment. The company’s therapeutic solution is capable of being the first septic shock treatment which is mechanism-based.

Fast Track designation permitted by FDA is aimed to expedite and facilitate review and development of new drugs to meet an unmet medical demand in treating a serious, life threatening condition for which clinical as well as non-clinical data has showcased the potential to acknowledge and fulfil that unmet medical need.

Co-founder and CEO at Inotrem, Jean-Jacques Garaud stated that FDA’s decision to grant the company a Fast Track designation for nangibotide development program is a significant recognition of the serious requirement for causal therapies in a critical condition like septic shock as well as Inotrem’s innovative treatment approach for managing acute inflammation.

CDO of Inotrem, Margarita Salcedo Magguilli stated that the company looks forward to collaborate with FDA and advance its planned ASTONISH trial, thereby expedite its efforts to deliver the first effective treatment option for the patients of septic shock.

Inotrem will start its planned multinational multicentric Phase IIb trial in patients of septic shock later in 2019. The Phase IIb trials would focus at showcasing nangibotide’s efficacy and provide a clinically relevant proof of the clinical activity in patients with septic shock.

 

Source credit: https://www.inotrem.com/wp-content/uploads/2019/08/Fast-Track.pdf



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...